Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexsero immune response and safety study in healthy Korean infants
2023-000764-58Phase 4
- Sponsor
- GSK
- Start
- Oct 2023
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meningococcal group B vaccine in meningococcal disease, sponsored by GSK. Primary endpoint: Humoral immune response after primary series and booster.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2023-000764-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000764-58.